FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093683062> ?p ?o ?g. }

• W2093683062 endingPage "1003" @default.
• W2093683062 startingPage "994" @default.
• W2093683062 abstract "Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in men affected by one or both conditions, without a significant increase in adverse events. However, the results are inconsistent. Perform a systematic review and meta-analysis of available prospective and cross-sectional studies on the use of PDE5-Is alone or in combination with α1-adrenergic blockers in patients with LUTS/benign prostatic hyperplasia (BPH). A systematic search was performed using the Medline, Embase, and Cochrane Library databases through September 2011 including the combination of the following terms: LUTS, BPH, PDE5-Is, sildenafil, tadalafil, vardenafil, udenafil, α-blockers, and α1-adrenergic blocker. The meta-analysis was conducted according to the guidelines for observational studies in epidemiology. Of 107 retrieved articles, 12 were included in the present meta-analysis: 7 on PDE5-Is versus placebo, with 3214 men, and 5 on the combination of PDE5-Is with α1-adrenergic blockers versus α1-adrenergic blockers alone, with 216 men. Median follow-up of all RCTs was 12 wk. Combining the results of those trials, the use of PDE5-Is alone was associated with a significant improvement of the International Index of Erectile Function (IIEF) score (+5.5; p < 0.0001) and International Prostate Symptom Score (IPSS) (−2.8; p < 0.0001) but not the maximum flow rate (Qmax) (−0.00; p = not significant) at the end of the study as compared with placebo. The association of PDE5-Is and α1-adrenergic blockers improved the IIEF score (+3.6; p < 0.0001), IPSS score (−1.8; p = 0.05), and Qmax (+1.5; p < 0.0001) at the end of the study as compared with α-blockers alone. The meta-analysis of the available cross-sectional data suggests that PDE5-Is can significantly improve LUTS and erectile function in men with BPH. PDE5-Is seem to be a promising treatment option for patients with LUTS secondary to BPH with or without ED." @default.
• W2093683062 created "2016-06-24" @default.
• W2093683062 creator A5012539089 @default.
• W2093683062 creator A5034704637 @default.
• W2093683062 creator A5042036655 @default.
• W2093683062 creator A5047934585 @default.
• W2093683062 creator A5049019006 @default.
• W2093683062 creator A5049759930 @default.
• W2093683062 creator A5056340385 @default.
• W2093683062 creator A5059786789 @default.
• W2093683062 creator A5080243444 @default.
• W2093683062 creator A5080620058 @default.
• W2093683062 creator A5081214299 @default.
• W2093683062 date "2012-05-01" @default.
• W2093683062 modified "2023-10-01" @default.
• W2093683062 title "A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia" @default.
• W2093683062 cites W1532389241 @default.
• W2093683062 cites W1559582992 @default.
• W2093683062 cites W1590209850 @default.
• W2093683062 cites W1730889413 @default.
• W2093683062 cites W1929501887 @default.
• W2093683062 cites W1964683861 @default.
• W2093683062 cites W1969673967 @default.
• W2093683062 cites W1986215651 @default.
• W2093683062 cites W1987068717 @default.
• W2093683062 cites W1994414216 @default.
• W2093683062 cites W1999691104 @default.
• W2093683062 cites W2014214578 @default.
• W2093683062 cites W2015122735 @default.
• W2093683062 cites W2016582498 @default.
• W2093683062 cites W2020241353 @default.
• W2093683062 cites W2020539470 @default.
• W2093683062 cites W2025969930 @default.
• W2093683062 cites W2027367061 @default.
• W2093683062 cites W2029280248 @default.
• W2093683062 cites W2049932762 @default.
• W2093683062 cites W2050093658 @default.
• W2093683062 cites W2051497077 @default.
• W2093683062 cites W2051838969 @default.
• W2093683062 cites W2053295331 @default.
• W2093683062 cites W2062498555 @default.
• W2093683062 cites W2069489942 @default.
• W2093683062 cites W2069963496 @default.
• W2093683062 cites W2072553225 @default.
• W2093683062 cites W2073978463 @default.
• W2093683062 cites W2074093603 @default.
• W2093683062 cites W2078469638 @default.
• W2093683062 cites W2086685901 @default.
• W2093683062 cites W2087575044 @default.
• W2093683062 cites W2106039105 @default.
• W2093683062 cites W2108696783 @default.
• W2093683062 cites W2151554163 @default.
• W2093683062 cites W2158861381 @default.
• W2093683062 cites W2807400090 @default.
• W2093683062 cites W2953200146 @default.
• W2093683062 doi "https://doi.org/10.1016/j.eururo.2012.02.033" @default.
• W2093683062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22405510" @default.
• W2093683062 hasPublicationYear "2012" @default.
• W2093683062 type Work @default.
• W2093683062 sameAs 2093683062 @default.
• W2093683062 citedByCount "274" @default.
• W2093683062 countsByYear W20936830622012 @default.
• W2093683062 countsByYear W20936830622013 @default.
• W2093683062 countsByYear W20936830622014 @default.
• W2093683062 countsByYear W20936830622015 @default.
• W2093683062 countsByYear W20936830622016 @default.
• W2093683062 countsByYear W20936830622017 @default.
• W2093683062 countsByYear W20936830622018 @default.
• W2093683062 countsByYear W20936830622019 @default.
• W2093683062 countsByYear W20936830622020 @default.
• W2093683062 countsByYear W20936830622021 @default.
• W2093683062 countsByYear W20936830622022 @default.
• W2093683062 countsByYear W20936830622023 @default.
• W2093683062 crossrefType "journal-article" @default.
• W2093683062 hasAuthorship W2093683062A5012539089 @default.
• W2093683062 hasAuthorship W2093683062A5034704637 @default.
• W2093683062 hasAuthorship W2093683062A5042036655 @default.
• W2093683062 hasAuthorship W2093683062A5047934585 @default.
• W2093683062 hasAuthorship W2093683062A5049019006 @default.
• W2093683062 hasAuthorship W2093683062A5049759930 @default.
• W2093683062 hasAuthorship W2093683062A5056340385 @default.
• W2093683062 hasAuthorship W2093683062A5059786789 @default.
• W2093683062 hasAuthorship W2093683062A5080243444 @default.
• W2093683062 hasAuthorship W2093683062A5080620058 @default.
• W2093683062 hasAuthorship W2093683062A5081214299 @default.
• W2093683062 hasConcept C121608353 @default.
• W2093683062 hasConcept C126322002 @default.
• W2093683062 hasConcept C126894567 @default.
• W2093683062 hasConcept C142724271 @default.
• W2093683062 hasConcept C158453852 @default.
• W2093683062 hasConcept C168563851 @default.
• W2093683062 hasConcept C170493617 @default.
• W2093683062 hasConcept C197934379 @default.
• W2093683062 hasConcept C204787440 @default.
• W2093683062 hasConcept C27081682 @default.
• W2093683062 hasConcept C2776235491 @default.
• W2093683062 hasConcept C2776478404 @default.
• W2093683062 hasConcept C2776547966 @default.

• next